急性缺血性卒中血管内治疗后血压管理:BEST-II随机临床试验
BEST-II为2期无效性试验,纳入120例成功血管内治疗的急性缺血性卒中患者,随机分入收缩压目标<140 mmHg、<160 mmHg或≤180 mmHg组。主要结局随访梗死体积和90天效用加权mRS的无效性检验均未达预设无效性标准,但未来优效性试验的预测成功概率较低。
要点
- 收缩压目标<140 mmHg组随访梗死体积均值32.4 mL,<160 mmHg组50.7 mL,≤180 mmHg组46.4 mL。
- 收缩压目标每降低1 mmHg,随访梗死体积斜率-0.29(95%CI -0.81至∞;无效性P=.99)。
- 与≤180 mmHg组比较,<140 mmHg组和<160 mmHg组未来试验预测成功概率分别为25%和14%。
核心结论
- 成功血管内治疗后收缩压目标<140 mmHg或<160 mmHg与≤180 mmHg相比,未达预设无效性标准,但未来更大试验中较低收缩压目标获益概率低。
研究设计与样本
- 随机、开放标签、盲法终点、2期无效性临床试验,于2020年1月至2022年3月在3个美国综合卒中中心纳入120例成功血管内治疗的急性缺血性卒中患者,最终随访2022年6月。
主要发现
- 随访梗死体积均值:<140 mmHg组32.4 mL(95%CI 18.0至46.7 mL),<160 mmHg组50.7 mL(95%CI 33.7至67.7 mL),≤180 mmHg组46.4 mL(95%CI 24.5至68.2 mL)。
- 效用加权mRS均值:<140 mmHg组0.51(95%CI 0.38至0.63),<160 mmHg组0.47(95%CI 0.35至0.60),≤180 mmHg组0.58(95%CI 0.46至0.71)。
- 校正基线Alberta卒中项目早期CT评分后,收缩压目标每降低1 mmHg随访梗死体积斜率-0.29(95%CI -0.81至∞;无效性P=.99)。
- 校正基线效用加权mRS后,收缩压目标每降低1 mmHg效用加权mRS斜率-0.0019(95%CI -∞至0.0017;无效性P=.93)。
- 与≤180 mmHg组比较,未来两组优效性试验预测成功概率<140 mmHg组为25%,<160 mmHg组为14%。
关键数值与推荐
- 无效性界限:随访梗死体积每20 mmHg收缩压目标降低增加10 mL(斜率0.5)或效用加权mRS降低0.10(斜率-0.005),单侧α=.05。
- 额外预设无效性标准:未来两组优效性试验预测成功概率<25%(效用加权mRS结局最大样本量1500)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effects of moderate systolic blood pressure (SBP) lowering after successful recanalization with endovascular therapy for acute ischemic stroke are uncertain. OBJECTIVE: To determine the futility of lower SBP targets after endovascular therapy (<140 mm Hg or 160 mm Hg) compared with a higher target (≤180 mm Hg). DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, blinded end point, phase 2, futility clinical trial that enrolled 120 patients with acute ischemic stroke who had undergone successful endovascular therapy at 3 US comprehensive stroke centers from January 2020 to March 2022 (final follow-up, June 2022). INTERVENTION: After undergoing endovascular therapy, participants were randomized to 1 of 3 SBP targets: 40 to less than 140 mm Hg, 40 to less than 160 mm Hg, and 40 to 180 mm Hg or less (guideline recommended) group, initiated within 60 minutes of recanalization and maintained for 24 hours. MAIN OUTCOMES AND MEASURES: Prespecified multiple primary outcomes for the primary futility analysis were follow-up infarct volume measured at 36 (±12) hours and utility-weighted modified Rankin Scale (mRS) score (range, 0 [worst] to 1 [best]) at 90 (±14) days. Linear regression models were used to test the harm-futility boundaries of a 10-mL increase (slope of 0.5) in the follow-up infarct volume or a 0.10 decrease (slope of -0.005) in the utility-weighted mRS score with each 20-mm Hg SBP target reduction after endovascular therapy (1-sided α = .05). Additional prespecified futility criterion was a less than 25% predicted probability of success for a future 2-group, superiority trial comparing SBP targets of the low- and mid-thresholds with the high-threshold (maximum sample size, 1500 with respect to the utility-weighted mRS score outcome). RESULTS: Among 120 patients randomized (mean [SD] age, 69.6 [14.5] years; 69 females [58%]), 113 (94.2%) completed the trial. The mean follow-up infarct volume was 32.4 mL (95% CI, 18.0 to 46.7 mL) for the less than 140-mm Hg group, 50.7 mL (95% CI, 33.7 to 67.7 mL), for the less than 160-mm Hg group, and 46.4 mL (95% CI, 24.5 to 68.2 mL) for the 180-mm Hg or less group. The mean utility-weighted mRS score was 0.51 (95% CI, 0.38 to 0.63) for the less than 140-mm Hg group, 0.47 (95% CI, 0.35 to 0.60) for the less than 160-mm Hg group, and 0.58 (95% CI, 0.46 to 0.71) for the high-target group. The slope of the follow-up infarct volume for each mm Hg decrease in the SBP target, adjusted for the baseline Alberta Stroke Program Early CT score, was -0.29 (95% CI, -0.81 to ∞; futility P = .99). The slope of the utility-weighted mRS score for each mm Hg decrease in the SBP target after endovascular therapy, adjusted for baseline utility-weighted mRS score, was -0.0019 (95% CI, -∞ to 0.0017; futility P = .93). Comparing the high-target SBP group with the lower-target groups, the predicted probability of success for a future trial was 25% for the less than 140-mm Hg group and 14% for the 160-mm Hg group. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke, lower SBP targets less than either 140 mm Hg or 160 mm Hg after successful endovascular therapy did not meet prespecified criteria for futility compared with an SBP target of 180 mm Hg or less. However, the findings suggested a low probability of benefit from lower SBP targets after endovascular therapy if tested in a future larger trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04116112.
引用
- Mistry EA, Hart KW, Davis LT, et al. Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial. JAMA. 2023. PMID: 37668620. doi:10.1001/jama.2023.14330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。